A rare entity

Sağcan, Fatih; Çıtak, Elvan Çağlar; Karpuz, Derya; Alakaya, Mehmet

doi:10.4103/jcrt.jcrt_26_18

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Buza et al have also reported that there are only case reports of sinus bradycardia with cisplatin in the literature [ 10 ]. The present data, although scarce, suggests screening all the patients for any heart-related illnesses and any rate-limiting drugs before commencing cisplatin-based regimens to minimize the risk of platinum-induced cardiotoxicity [ 11 , 12 ]. Patients receiving such regimens should be monitored closely for left ventricular ejection fraction, and ECG monitoring should be employed for early detection to reduce drug-related complications and for better outcomes [ 6 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases

Naeem¹,

Azhar²,

Baloch³

et al. 2021

Cureus

View full text Add to dashboard Cite

Cisplatin is a platinum-containing drug that inhibits DNA synthesis by inhibiting cross-linking, denaturing DNA strands. It is used in combination with other chemotherapeutic agents to treat several types of cancers. Numerous adverse effects have been reported with this compound. However, it is considered a safe medication in terms of cardiotoxicity. In this report, we discuss the case of two patients who experienced bradycardia while receiving cisplatin as part of combination therapy. A workup was undertaken to rule out other possible causes of bradycardia, and the diagnosis of cisplatin-induced bradycardia was made.

show abstract

Section: Discussionmentioning

confidence: 99%

Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases

Naeem¹,

Azhar²,

Baloch³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…In large retrospective study patients who received cisplatin had 4 times increased risk of developing atrial fibrillation ( 130 ). And in addition, at least three case reports of cisplatin induced bradycardia were reported, in two cases even with a necessary pacemaker implantation for atrioventricular block ( 131 , 132 ).…”

Section: Introductionmentioning

confidence: 99%

Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future

Rihackova,

Rihacek,

Vyskocilova

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.

show abstract

Cisplatin

2020

Reactions Weekly

View full text Add to dashboard Cite

A rare entity

Cited by 3 publications

References 3 publications

Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases

Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases

Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future

Cisplatin

Contact Info

Product

Resources

About